Setterwalls has advised Trill Impact in connection with a private placement in Cinclus Pharma

The directed issue amounts to approximately SEK 240 million and was directed to shareholders as well as to new investors. The purpose of the private placement is to raise capital to be used to accelerate the Cinclus’ commercialization strategy and to broaden the shareholder base.

Cinclus Pharma Holding AB is a clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases, including novel treatment for gastroesophageal reflux disease (“GERD”). The proceeds from the private placements will be used to fund the further clinical development of X842, a clinical-stage drug candidate for the treatment of GERD.

Setterwalls advised the lead investor in the round, Trill Impact, a pioneering Impact House with more than EUR 1 billion in assets under management across multiple investment strategies aiming to be a force for positive change and realize the vision of delivering real returns and lasting impact.